-
Full Article (HTML) (36) -
Full Article (PDF) (6)
Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Checklist of Responsibilities for the Scientific Editor of This Article
Publishing Process of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3528)
All Articles published online
|
Publishing Process of This Article
|
Nov 14, 2015 (publication date) through May 27, 2020
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| Number | Cited Articles |
| 1 |
Chang-Jiang Lei, Jia-Ni Liu, Rong Wu, Zhi-Xiong Long, Jiang-Zhou Zhang, Dan Tao, Yan-Ping Liu. Change of the peripheral blood immune pattern and its correlation with prognosis in patients with liver cancer treated by sorafenib. Asian Pacific Journal of Tropical Medicine 2016; 9(6): 592 doi: 10.1016/j.apjtm.2016.04.019
|
| 2 |
Hongyong Zhang, Yufeng Wang, Yanxia Bai, Yuan Shao, Jigang Bai, Zhenhua Ma, Qingguang Liu, Shengli Wu. Recombinant adeno-associated virus expressing a p53-derived apoptotic peptide (37AA) inhibits HCC cells growth in vitro and in vivo. Oncotarget 2017; 8(10): 16801 doi: 10.18632/oncotarget.15160
|
| 3 |
Shanshan Jiang, Qian Wang, Meiqing Feng, Jiyang Li, Zhongbin Guan, Duopeng An, Mengxue Dong, Yuzhe Peng, Kudelaidi Kuerban, Li Ye. C2-ceramide enhances sorafenib-induced caspase-dependent apoptosis via PI3K/AKT/mTOR and Erk signaling pathways in HCC cells. Applied Microbiology and Biotechnology 2017; 101(4): 1535 doi: 10.1007/s00253-016-7930-9
|
| 4 |
Diego Almanza, Mehrnaz Gharaee-Kermani, Alisa Zhilin-Roth, Jose A. Rodriguez-Nieves, Cory Colaneri, Todd Riley, Jill A. Macoska. Nonalcoholic Fatty Liver Disease Demonstrates a Pre-fibrotic and Premalignant Molecular Signature. Digestive Diseases and Sciences 2019; 64(5): 1257 doi: 10.1007/s10620-018-5398-4
|
| 5 |
Bijay Dhungel, Charmaine A. Ramlogan-Steel, Christopher J. Layton, Jason C. Steel. MicroRNA199a-Based Post-transcriptional Detargeting of Gene Vectors for Hepatocellular Carcinoma. Molecular Therapy - Nucleic Acids 2018; 13: 78 doi: 10.1016/j.omtn.2018.08.016
|
| 6 |
Mohammed K. AbdElhameid, Madlen B. Labib, Ahmed T. Negmeldin, Muhammad Al-Shorbagy, Manal R. Mohammed. Design, synthesis, and screening of ortho-amino thiophene carboxamide derivatives on hepatocellular carcinomaas VEGFR-2Inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry 2018; 33(1): 1472 doi: 10.1080/14756366.2018.1503654
|
| 7 |
Fang Wang, Thomas Bank, Gregory Malnassy, Maribel Arteaga, Na Shang, Annika Dalheim, Xianzhong Ding, Scott J. Cotler, Mitchell F. Denning, Michael I. Nishimura, Peter Breslin, Wei Qiu. Inhibition of insulin‐like growth factor 1 receptor enhances the efficacy of sorafenib in inhibiting hepatocellular carcinoma cell growth and survival. Hepatology Communications 2018; 2(6): 732 doi: 10.1002/hep4.1181
|
| 8 |
Liyu Shi, Xiaoqiu Zheng, Yuzhuo Fan, Xiaolan Yang, Aimei Li, Jun Qian. The contribution of miR-122 to the innate immunity by regulating toll-like receptor 4 in hepatoma cells. BMC Gastroenterology 2019; 19(1) doi: 10.1186/s12876-019-1048-3
|
| 9 |
Tian-yi Zhou, Lin-han Zhuang, Yan Hu, Yu-lu Zhou, Wen-kai Lin, Dan-dan Wang, Zi-qian Wan, Lin-lin Chang, Ying Chen, Mei-dan Ying, Zi-bo Chen, Song Ye, Jian-shu Lou, Qiao-jun He, Hong Zhu, Bo Yang. Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells. Scientific Reports 2016; 6(1) doi: 10.1038/srep30483
|
| 10 |
Menelaos Zafrakas, Panayiota Papasozomenou, Christos Emmanouilides. Sorafenib in breast cancer treatment: A systematic review and overview of clinical trials. World Journal of Clinical Oncology 2016; 7(4): 331-336 doi: 10.5306/wjco.v7.i4.331
|
| 11 |
MK Morris, DC Clarke, LC Osimiri, DA Lauffenburger. Systematic Analysis of Quantitative Logic Model Ensembles Predicts Drug Combination Effects on Cell Signaling Networks. CPT: Pharmacometrics & Systems Pharmacology 2016; 5(10): 544 doi: 10.1002/psp4.12104
|
| 12 |
Yaoye Tao, Jianguo Wang, Xiao Xu. Emerging and Innovative Theranostic Approaches for Mesoporous Silica Nanoparticles in Hepatocellular Carcinoma: Current Status and Advances. Frontiers in Bioengineering and Biotechnology 2020; 8 doi: 10.3389/fbioe.2020.00184
|
| 13 |
Maximilian A. Ardelt, Thomas Fröhlich, Emanuele Martini, Martin Müller, Veronika Kanitz, Carina Atzberger, Petra Cantonati, Martina Meßner, Laura Posselt, Thorsten Lehr, Jan-Georg Wojtyniak, Melanie Ulrich, Georg J. Arnold, Lars König, Dario Parazzoli, Stefan Zahler, Simon Rothenfußer, Doris Mayr, Alexander Gerbes, Giorgio Scita, Angelika M. Vollmar, Johanna Pachmayr. Inhibition of Cyclin-Dependent Kinase 5: A Strategy to Improve Sorafenib Response in Hepatocellular Carcinoma Therapy. Hepatology 2019; 69(1): 376 doi: 10.1002/hep.30190
|
| 14 |
Beste Yurdacan, Unal Egeli, Gamze Guney Eskiler, Isil Ezgi Eryilmaz, Gulsah Cecener, Berrin Tunca. Investigation of new treatment option for hepatocellular carcinoma: a combination of sorafenib with usnic acid. Journal of Pharmacy and Pharmacology 2019; 71(7): 1119 doi: 10.1111/jphp.13097
|
| 15 |
Sara Jaramillo, Francisco J.G. Muriana, Rafael Guillen, Ana Jimenez-Araujo, Rocio Rodriguez-Arcos, Sergio Lopez. Saponins from edible spears of wild asparagus inhibit AKT, p70S6K, and ERK signalling, and induce apoptosis through G0/G1 cell cycle arrest in human colon cancer HCT-116 cells. Journal of Functional Foods 2016; 26: 1 doi: 10.1016/j.jff.2016.07.007
|
| 16 |
Rui Zhang, Min Ma, Gang Dong, Rong‐Rong Yao, Jing‐Huan Li, Qiong‐Dan Zheng, Yin‐Ying Dong, Hui Ma, Dong‐Mei Gao, Jie‐Feng Cui, Zheng‐Gang Ren, Rong‐Xin Chen. Increased matrix stiffness promotes tumor progression of residual hepatocellular carcinoma after insufficient heat treatment. Cancer Science 2017; 108(9): 1778 doi: 10.1111/cas.13322
|
| 17 |
Francesca Mastropasqua, Flaviana Marzano, Alessio Valletti, Italia Aiello, Giuseppe Di Tullio, Annalisa Morgano, Sabino Liuni, Elena Ranieri, Luisa Guerrini, Giuseppe Gasparre, Elisabetta Sbisà, Graziano Pesole, Antonio Moschetta, Mariano Francesco Caratozzolo, Apollonia Tullo. TRIM8 restores p53 tumour suppressor function by blunting N-MYC activity in chemo-resistant tumours. Molecular Cancer 2017; 16(1) doi: 10.1186/s12943-017-0634-7
|
| 18 |
Ming-Hua Hsu, Shih-Ming Hsu, Yu-Cheng Kuo, Chih-Yu Liu, Cheng-Ying Hsieh, Yuh-Ching Twu, Chung-Kwe Wang, Yuan-Hsi Wang, Yi-Jen Liao. Treatment with low-dose sorafenib in combination with a novel benzimidazole derivative bearing a pyrolidine side chain provides synergistic anti-proliferative effects against human liver cancer. RSC Advances 2017; 7(26): 16253 doi: 10.1039/C6RA28281D
|
| 19 |
Zhuona Rong, Tingting Fan, Huiling Li, Juan Li, Kangwei Wang, Xinxin Wang, Jianyi Dong, Jun Chen, Fujin Wang, Jingyu Wang, Aiguo Wang. Differential Proteomic Analysis of Gender-dependent Hepatic Tumorigenesis in Hras12V Transgenic Mice. Molecular & Cellular Proteomics 2017; 16(8): 1475 doi: 10.1074/mcp.M116.065474
|
| 20 |
Shunnan Yao, Jianpin Ye, Mengqi Yin, Rui Yu. DMAMCL exerts antitumor effects on hepatocellular carcinoma both in vitro and in vivo. Cancer Letters 2020; 483: 87 doi: 10.1016/j.canlet.2020.04.003
|
| 21 |
Zhao-Shan Niu, Xiao-Jun Niu, Wen-Hong Wang. Genetic alterations in hepatocellular carcinoma: An update. World Journal of Gastroenterology 2016; 22(41): 9069-9095 doi: 10.3748/wjg.v22.i41.9069
|
| 22 |
Peter Dietrich, Andreas Koch, Valerie Fritz, Arndt Hartmann, Anja Katrin Bosserhoff, Claus Hellerbrand. Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance. Gut 2018; 67(7): 1328 doi: 10.1136/gutjnl-2017-315402
|
| 23 |
Peter Dietrich, Kim Freese, Abdo Mahli, Wolfgang Erwin Thasler, Claus Hellerbrand, Anja Katrin Bosserhoff. Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic “dual-hit” option. Oncotarget 2018; 9(3): 3605 doi: 10.18632/oncotarget.23188
|
| 24 |
Jing Li, Jinfeng Wang, Wei Zhou, Shuqin Zhang, Yuan Le, Rong He. Downregulation of BRAF-activated non-coding RNA suppresses the proliferation, migration and invasion, and induces apoptosis of hepatocellular carcinoma cells. Oncology Letters 2017; 14(4): 4751 doi: 10.3892/ol.2017.6770
|
| 25 |
Alicia Bort, Elena Spínola, Nieves Rodríguez-Henche, Inés Díaz-Laviada. Capsaicin exerts synergistic antitumor effect with sorafenib in hepatocellular carcinoma cells through AMPK activation. Oncotarget 2017; 8(50): 87684 doi: 10.18632/oncotarget.21196
|
| 26 |
Shuzhen Chen, Qiqi Cao, Wen Wen, Hongyang Wang. Targeted therapy for hepatocellular carcinoma: Challenges and opportunities. Cancer Letters 2019; 460: 1 doi: 10.1016/j.canlet.2019.114428
|
| 27 |
Guirong Zheng, Ruirui Zhao, Aixiao Xu, Zhichun Shen, Xian Chen, Jingwei Shao. Co-delivery of sorafenib and siVEGF based on mesoporous silica nanoparticles for ASGPR mediated targeted HCC therapy. European Journal of Pharmaceutical Sciences 2018; 111: 492 doi: 10.1016/j.ejps.2017.10.036
|